source
- Bausch + Lomb and Celldex rocked by respective phase 2 flopsBausch + Lomb and Celldex have independently reported phase 2 flops. While Celldex ended work in the indication in response to the setback, Bausch + Lomb noted numerical improvements and explorator…Fierce Biotech · 7h ago↗ source
- US panel warns China’s biotech plan could dominate sector and threaten drug supply chainA congressional commission has warned that China’s new five-year biotech plan could allow it to dominate the global drug market. The commission says the strategy could leave U.S. patients vulnerab…